检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:刘曼华[1] 冯一中[1] 程英[2] 韩枋[2] 季小华[2] 耿淑萍[2] 陶潜[2]
机构地区:[1]苏州大学医学院病理学教研室,苏州215007 [2]南通医学院附属二院,江苏南通226000
出 处:《苏州大学学报(医学版)》2002年第2期179-179,共1页Suzhou University Journal of Medical Science
摘 要:目的 探讨c -myc ,c -erbB - 2两种癌基因在宫颈癌中表达及其临床意义。 方法 应用免疫组化法检测宫颈癌组织与CIN、正常宫颈组织标本中c -myc ,c-erbB - 2蛋白的表达 ,分析这两种蛋白表达与临床病理及预后的关系。结果 宫颈癌组织c -myc蛋白表达率 :宫颈癌组织为 40 .0 0 %,正常宫颈组织为 10 .0 0 %,CIN为2 0 .0 0 %,表达与病理分类有关 ,腺癌表达率高于鳞癌 ,但差异无显著性 (P >0 .0 5 ) ;过表达与临床分期及病理学分级相关 (P <0 .0 5 )。宫颈癌组织c -erbB - 2表达率为 37.5 0 %,正常宫颈组织未见阳性表达 ,仅 1例重度CIN弱表达 ,腺癌表达率 (6 6 .6 7%)高于鳞癌 (32 .35 %) ,但无显著性差异 (P >0 .0 5 ) ,鳞癌过表达与复发有关。C -myc ,c -erbB - 2两种基因在宫颈癌中表达差异无显著性 (P >0 .0 5 )。结论 C -myc表达与宫颈癌发生发展有一定关系 ;c-erbB - 2表达是细胞恶性变的标志 ,宫颈鳞癌中过表达与复发有关。Objective To investigate the expressions of c-myc and c-erbB-2 in cervical carcinoma and their significance.Method Expression of c-myc. and c-erbB-2 proteins was examined immunohistochemically in 40 cases of carcinoma of the uterine cervix and 10 cases of CIN and 10 cases of cervical epithelium. The relationship between their expression with clinicpathologic factors and prognosis was analyzed by chi-square test.Results The expression rate of c-myc was 40.00% in cervical carcinoma and 20.00% in CIN and 10.00% in cervical epithelium(P<0.05). The expression was in connection with histological grade and clinic types.(P<0.05).The expression rate of c-erbB-2 was37.50% in cervical carcinoma and was none in cervical epithelium.and was10.00% in CIN. The expression of squamous cell carcinoma was in connection with relapse.There was no relationship between expression of C-myc and c-erbB-2(P>0.05).Conclusion Expression of c-myc is relevant to progression of cervical carcinoma; Expression of c-erbB-2 is a signal of cells become malignant and is relevant to relapse in squamous cell carcinoma.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.117